Pharmaceutical

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

Staff June 9, 2023

Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to...

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

Staff June 9, 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...

Extraordinary General Meeting of Infant Bacterial Therapeutics

Staff June 9, 2023

At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve...

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Staff June 9, 2023

Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination...

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

Staff June 9, 2023

A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical...

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Staff June 9, 2023

Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities...

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Staff June 8, 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...

Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

Staff June 8, 2023

Association with the Chamber Will Improve Visibilityand Could Lead to Potential Collaborations BEIJING, June 08, 2023 (GLOBE NEWSWIRE) -- Shineco,...

Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023

Staff June 7, 2023

SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting...

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

Staff June 7, 2023

ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBDSOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE)...

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Staff June 7, 2023

PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), a clinical-stage drug discovery company developing...

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

Staff June 7, 2023

SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical...

ODAIA Adds Demonstrated Industry Talent Following Successful Series B

Staff June 6, 2023

Rebecca Skvorc named Chief Financial OfficerJim Diefenbach named SVP of SalesMike Goulart named Sr. Director, Business AccelerationTORONTO, June 06, 2023...

Lucy Scientific Discovery to Present at the LD Micro Invitational XIII Conference on June 7

Staff June 6, 2023

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a leader in natural and...

Baudax Bio Announces Date of Reconvened Annual Meeting

Staff June 6, 2023

Annual Meeting to be reconvened on June 23, 2023MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX)...

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

Staff June 6, 2023

Gray brings significant biotech financial and operations experience to Carmot to advance a clinical pipeline of therapies to treat people...

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Staff June 6, 2023

Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1...

Pharmaceutical

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

Extraordinary General Meeting of Infant Bacterial Therapeutics

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

ODAIA Adds Demonstrated Industry Talent Following Successful Series B

Lucy Scientific Discovery to Present at the LD Micro Invitational XIII Conference on June 7

Baudax Bio Announces Date of Reconvened Annual Meeting

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Healthmap Solutions Names Eli Wahesh as Chief Operating Officer

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Luna Announces Impactful Collaborations with Accountable Care Organizations (ACOs)

Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer’s Patients

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

You may have missed